GlassScriptPhysician profile
Puja Gurung
NPI 1063727832
$2,103.12
in general payments reported to CMS, 2019-2025
30 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Sleep Medicine (Family Medicine) provider received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.05 · 2021: $83.50 · 2022: $142 · 2023: $508 · 2024: $744 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520 · Travel and Lodging: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.05 |
| Travel and Lodging | $335.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $566.10 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $278.08 | 2021-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $263.54 | 2023-2024 | |
| Resmed Corp | $135.87 | 2021-2024 | |
| Axsome Therapeutics, INC. | $98.37 | 2024-2025 | Sunosi |
| Neurelis, INC. | $95.12 | 2023-2025 | Valtoco |
| Ucb, INC. | $79.70 | 2022-2024 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $53.50 | 2023-2025 | Austedo Xr, Austedo Xr |
| Avadel Cns Pharmaceuticals, LLC | $45.97 | 2024-2025 | Lumryz |
| Neurocrine Biosciences, INC. | $39.18 | 2023 | Ingrezza, Ongentys |
| Lundbeck LLC | $37.86 | 2024-2025 | Vyepti |
| Biogen, INC. | $34.63 | 2023 | Spinraza |
| Sk Life Science, INC. | $30.97 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.27 | 2022 | |
| Tanabe Pharma America, INC. | $25.56 | 2025 | Radicava |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $24.86 | 2023 | Trudhesa |
| Abbott Laboratories | $24.64 | 2024 | Infinity |
| Itamar Medical INC | $22.61 | 2023 | Watchpatone |
| Amgen INC. | $22.16 | 2022 | |
| Alk-Abello, INC | $22.05 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.83 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $20.81 | 2024 | |
| Fisher & Paykel Healthcare INC | $20.29 | 2022 | |
| Abbvie INC. | $19.13 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.33 | 2023 | Keveyis |
| Grifols USA, LLC | $16.68 | 2024 | Gamunex-C |
| Avanir Pharmaceuticals, INC. | $15.63 | 2022 | |
| Acorda Therapeutics, INC | $14.66 | 2023 | Inbrija |
| Pfizer INC. | $14.56 | 2023 | |
| Boston Scientific Corporation | $14.16 | 2024 | Vercise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puja Gurung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.